Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

Summary

The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (\>= 4), before the first vaccination (T0), after the second MenBvac vaccination (6 weeks after the second vaccination), before the third MenBvac vaccination and after the third MenBvac vaccination (6 weeks after the second vaccination) and one year after the third menBvac vaccination.

Timeline

Start

2009-04

Primary completion

2010-10

Completion

2011-01

Publications

• Results Caron F, Delbos V, Houivet E, Deghmane AE, Leroy JP, Hong E, Benichou J, Taha MK. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine. 2012 Jul 20;30(34):5059-62. doi: 10.1016/j.vaccine.2012.05.051. Epub 2012 May 30.

Drugs

Indications

No indication recorded.